Advertisement

Make Big Pharma great again

Britain’s big drug companies lead the world, but they are stagnating, says Matthew Lynn. Time for a shake-up.

907-Walmsley-634
Emma Walmsley: pondering a break-up

Britain's big drug companies lead the world, but they are stagnating. Time for a shake-up.

With a combination of brilliant research and development (R&D), high-end manufacturing, and savvy marketing, this country has built a fantastically successful group of major drugs firms. Glaxo created the world's biggest selling medicine, the ulcer treatment Zantac, and used that as a platform to create what for a time was one of the country's largest companies. AstraZeneca built an unbeatable franchise in cancer and ulcer medicines to become one of the world's largest drugs groups. Shire carved out a position in hyperactivity medicines that catapulted it into the big league in just a few years. The industry has been an outstanding success story, creating plenty of wealth for shareholders, lots of well-paid jobs, and a steady flow of exports. But there is a problem.

There may be trouble ahead

Take the UK's two biggest companies. Glaxo has been through two huge mergers, first with Wellcome and then with SmithKline, to become GlaxoSmithKline (GSK), but emerged from the process not much larger than when it started and certainly not more successful. It has been drifting aimlessly for years. Over the last five years a strong bull market the shares have drifted down from £17 to £15. Back in August 1998 they were trading at £18. Over two decades they have gone nowhere. Sure, the company has churned out reliable dividends. With a 5% yield, it has become a utility rather than a growth business. But it has been a dismal performance.

Advertisement - Article continues below
Advertisement
Advertisement - Article continues below

In the last few weeks, its chief executive, Emma Walmsley, has been toying with the idea of breaking it up, splitting out the consumer unit that includes brands such as Horlicks and Night Nurse from its prescription business. So far that has been rejected, with the company instead betting on a cost restructuring and another massive investment in genetics to try and turbo-charge its discovery process. Will that work? Perhaps. But it is pretty much what GSK has been doing for 20 years and there is not much reason to expect better results this time around.

AstraZeneca has done better, but has hardly been setting the world alight. Its latest results were disappointing. Drug sales were down by 2%, and core operating profits by 34%. Some of its new drugs such as the lung-cancer treatment Tagrisso are starting to perform well, but as it loses patents elsewhere overall sales are still declining. That is hardly encouraging.

Stop the slide into irrelevance

Twenty years ago, pharmaceuticals was a growth business. It still should be. Populations are ageing rapidly and older people need a lot more medical care. Health systems are consuming increasing percentages of GDP in every major developed country. The drugs giants should be growing at a decent clip. Instead they are stagnating.

Advertisement - Article continues below

Only four years ago, the City allowed AstraZeneca to fend off a £69bn hostile bid from Pfizer. It accepted the argument that the company had a brighter future standing alone. Shareholders have supported GSK through a couple of decades of bids and deals, relaunches and restructurings without having very much to show for all that patience. But the formula clearly isn't working any more. Both companies are weighed down by expiring patents and sluggish R&D.

Earlier this year, the third major British drugs company, Shire, was sold to Japan's Takeda for £46bn, a huge premium to its price before the deal was announced. A sale might well the best solution for the other two remaining UK giants as well. Both of them are still strong enough to command a good price if there was a competitive auction. But there are other solutions as well. Both companies could be demerged into smaller units, perhaps focused on specific diseases. That way they would be a lot nimbler, and potentially a lot more innovative as well. The City has given both companies plenty of time to reinvent themselves. Now it is time to insist on new management, a sale or a break-up. Otherwise one of the UK's most successful industries will slide into irrelevance.

Advertisement
Advertisement

Recommended

How long can the good times roll?
Economy

How long can the good times roll?

Despite all the doom and gloom that has dominated our headlines for most of 2019, Britain and most of the rest of the developing world is currently en…
19 Dec 2019
The British equity market is shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Beyond the Brexit talk, the British economy isn’t doing too badly
Economy

Beyond the Brexit talk, the British economy isn’t doing too badly

The political Brexit pantomime aside, Britain is in pretty good shape. With near-record employment, strong wage growth and modest inflation, there is …
17 Oct 2019
UK house prices hit a new record high – can it last?
House prices

UK house prices hit a new record high – can it last?

Despite the pandemic, UK house prices have hit a new high. John Stepek looks at what’s driving the surge in prices, and what it means for house prices…
7 Aug 2020

Most Popular

Don’t despair on dividends – these companies could be set to bring them back
Income investing

Don’t despair on dividends – these companies could be set to bring them back

The value of dividends paid out by UK stocks has plummeted this year as companies “rebase” their payment policies. But things could soon start to look…
6 Aug 2020
Platinum: the precious metal that looks set to play catch-up with silver and gold
Silver and other precious metals

Platinum: the precious metal that looks set to play catch-up with silver and gold

Gold and silver continue to soar, but there's still time to get in. And there's another precious metal that looks set to go on a bull run too, says Jo…
7 Aug 2020
The MoneyWeek Podcast: how to age well and profit from the “longevity dividend”
Investment strategy

The MoneyWeek Podcast: how to age well and profit from the “longevity dividend”

Merryn talks to economist and author Andrew J Scott and discusses how we can profit from the "longevity dividend" as we live longer; why we need to re…
6 Aug 2020